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Xiamenmycin Attenuates Hypertrophic Scars by
Suppressing Local Inflammation and the Effects of
Mechanical Stress
Xiao-Jin Liu1,2,7, Min-Juan Xu3,7, Si-Teng Fan4, Zheng Wu1,5, Jun Li1, Xiao-Mei Yang1, Ya-Hui Wang1,
Jun Xu6 and Zhi-Gang Zhang1
Hypertrophic scarring is a common disease affecting millions of people around the world, but there are currently
no satisfactory drugs to treat the disease. Exaggerated inflammation and mechanical stress have been shown to
be two main mechanisms of excessive fibrotic diseases. Here we found that a benzopyran natural product,
xiamenmycin, could significantly attenuate hypertrophic scar formation in a mechanical stretch-induced mouse
model. The compound suppressed local inflammation by reducing CD4þ lymphocyte and monocyte/macro-
phage retention in fibrotic foci and blocked fibroblast adhesion with monocytes. Both in vivo and in vitro studies
found that the compound inhibited the mechanical stress-induced profibrotic effects by suppressing prolifera-
tion, activation, fibroblast contraction, and inactivating FAK, p38, and Rho guanosine triphosphatase signaling.
Taken together, the compound could simultaneously suppress both the inflammatory and mechanical stress
responses, which are the two pivotal pathological processes in hypertrophic scar formation, thus suggesting that
xiamenmycin can serve as a potential agent for treating hypertrophic scar formation and other excessive fibrotic
diseases.
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INTRODUCTION
Hypertrophic scarring (HPS) is a result of increased fibrogen-
esis, which is thought to be caused by an exaggerated
inflammatory response, usually secondary to trauma or surgi-
cal procedures. It not only causes disfigurement (Lawrence
et al., 2012) but also dysfunction of affected organs (Van Loey
and Van Son, 2003). Current therapeutic approaches include
surgical procedures, anti-inflammatory drugs, cytotoxic drugs,
superficial compression therapy, and radiation therapy.
However, none of them currently give satisfactory results.
This deficiency is largely because of a poor understanding of
the mechanisms of HPS formation (Profyris et al., 2012;
Tziotzios et al., 2012).
Recently, mechanical stress has been demonstrated to be
crucial for HPS formation (Aarabi et al., 2007b; Hinz, 2009;
Gurtner et al., 2011; Ogawa et al., 2012; Wynn and
Ramalingam, 2012), suggesting that inflammation and
mechanical stress could be two main pathways for
therapeutic interventions. The well-known anti-inflammatory
drugs such as corticosteroids are not suitable for high dosages
and long-term use, and superficial compression is
inappropriate for scars on large surface area or in visceral
organs. Therefore, bioactive compounds with activities against
both inflammation and mechanical stress would be more
effective in the management of HPS (Mustoe et al., 2002;
Ogawa, 2010; Wynn and Ramalingam, 2012).
Our recent study (Xu et al., 2012) described the discovery
of a bioactive natural product of the benzopyran skeleton,
named xiamenmycin, which was isolated from the mangrove-
derived Streptomyces xiamenensis. The compound has been
reported as an inhibitor of ICAM-1/LFA-1 interaction
(Kawamura et al., 2000), which is suggestive of an anti-
inflammatory role (Long, 2011). Our previous study showed
that xiamenmycin not only blocked the adhesion of
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monocytes to lung fibroblasts but also inhibited the contractile
ability of lung fibroblasts (Xu et al., 2012). Therefore, these
findings motivated us to explore its potential usage as an anti-
HPS drug aimed at suppressing both inflammation and
mechanical stress.
To investigate whether xiamenmycin can be used as an
anti-HPS drug, we examined its effects on mechanical stress
and inflammation in association with various fibroblast cel-
lular behaviors, that is, proliferation, activation, contraction,
and adhesion to human acute monocytic leukemia cells (THP-
1), and the signaling pathways involved in its inhibitory effects
on HPS formation.
RESULTS
Xiamenmycin inhibits scar formation in a mechanical stretch-
induced mouse model
A mechanical stretch-induced mouse HPS model satisfactorily
simulates mechanical stretching, as well as a prolonged
inflammatory and proliferation phase (Aarabi et al., 2007a).
Therefore, this system is an ideal model for screening anti-HPS
drugs in vivo.
We investigated the antifibrotic effects of xiamenmycin
on the model during the proliferation stage of scar formation.
After 10 days (from post-incision day 4 to day 14) of
intraperitoneal administration of xiamenmycin, the mice
treated with xiamenmycin displayed significantly reduced
scar formation compared with DMSO-treated mice, as
defined by a lower average gross scar area at all
examined time points (post-incision day 14,
18.436±7.899 mm2 vs 39.466±13.980 mm2, Po0.05; post-
incision day 21, 14.154±3.447 mm2 vs 27.476±4.340 mm2,
Po0.01; post-incision day 28, 10.054±2.337 mm2 vs
20.920±2,431 mm2, Po0.01) (Figure 1a–c) and lower
scar elevation index (at post-incision day 14, 1.640±0.305
vs 2.746±0.676, Po0.05; at post-incision day 28,
1.394±0.346 vs 2.353±0.452, Po0.01) (Figure 1d and e).
Magnified images show that the characteristic HPS structure–
collagen whorl disappeared following xiamenmycin
treatment, but remained in mice treated with DMSO
(Figure 1f).
No significant differences in body weight or Body Condition
Scoring were found before or after drug administration
between both groups (data not shown). These results indicate
that xiamenmycin can significantly inhibit mechanical stretch-
induced scar formation in vivo but does not significantly affect
the general health of mice.
To assess the toxicity of xiamenmycin, we measured the
half-maximal inhibitory concentration (IC50) of the compound
before conducting cellular experiments, and the IC50 of
xiamenmycin was 240mg ml1. Therefore, we adopted
30mg ml1 as the maximal concentration used in cellular
experiments. To further evaluate its cytotoxicity, in vitro total
protein synthesis assays were performed after treatment with
xiamenmycin at 0, 5, 10, and 30mg ml 1. After a 3-day
incubation, the total protein level of human dermal fibroblasts
(HDFs) was not significantly affected by xiamenmycin
(Figure 2e).
Xiamenmycin suppresses inflammatory cell retention in
proliferation-stage scar foci and blocks adhesion between HDFs
and THP-1
Prolonged and excessive inflammation has a substantial role in
HPS formation. CD4þ T lymphocytes and monocytes/macro-
phages are the predominant inflammatory cells that may be
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Figure 1. Xiamenmycin attenuates hypertrophic scar formation in a
mechanical stretch-induced mouse model. (a, b) Images of scars and
Picrosirius red staining sections at day 14 post incision. (a) Bar¼2.5mm; (b)
bar¼ 200mm. The dashed lines indicate the scar borders. (c, d) Gross scar area
and scar elevation index (SEI) of xiamenmycin- and DMSO-treated mice. n¼ 5.
Values are denoted as means±SD. *Po0.05, **Po0.01. (e) Images indicating
the measurement of SEI at day 14 post incision. ‘‘D’’ indicates the scar
thickness, and ‘‘d’’ indicates the thickness of adjacent normal skin. SEI is the
ratio of D/d. (f) Images show the collagen structure in xiamenmycin- and
DMSO-treated mice scar. The collagen whorl is indicated by a black rectangle.
Bar¼10mm.
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involved in maintaining the chronic inflammatory status of
HPS (Wang et al., 2007; Wynn and Barron, 2010; Wong et al.,
2011). Immunohistochemistry data indicated that the CD4þ
cells and MOMA2þ cells in xiamenmycin-treated mouse scar
tissues were significantly reduced, compared with those in
DMSO-treated tissues at post-incision day 14 (1.25±0.957 vs
5±0.816 CD4þ cells per field, Po0.01 and 0.75±0.957 vs
4.5±1.291 MOMA2þ cells per field, Po0.01, respectively)
and post-incision day 28 (1.8±1.304 vs 5±1.581 CD4þ
cells per field, Po0.01 and 1.6±1.140 vs 4.2±0.837
MOMA2þ cells per field, Po0.01, respectively) (Figure 2a
and b). Further in vitro adhesion assays of THP-1 and HDFs
confirmed that xiamenmycin can reduce the rate of adhesion
in a dose-dependent manner (Figure 2c and d). These findings
demonstrate that xiamenmycin can suppress the inflammatory
response by reducing the recruitment of inflammatory cells
and inhibiting direct interactions between inflammatory cells
and fibroblasts.
Xiamenmycin inhibits fibroblast proliferation
Fibroblasts are the predominant mesenchymal cells in the
dermis, and their proliferation, activation, apoptosis, and
survival are strongly implicated in HPS formation (Sarrazy
et al., 2011). To investigate the effects of xiamenmycin on
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Figure 2. Xiamenmycin reduces retention of inflammatory cells and adhesion between human acute monocytic leukemia cell line (THP-1) cells and
human dermal fibroblasts (HDFs). (a) Immunohistochemical staining of CD4- or MOMA2-positive cells in DMSO- or xiamenmycin-treated scar tissue of
post-incision day 14. Arrowheads indicate the positive cells. Bar¼50mm. (b) Quantification of CD4- or MOMA2-positive cells of post-incision days 14 and 28.
n¼ 5. Values are means±SD. **Po0.01. (c) Representative images of adhesion assays. Green spots are calcein AM-labeled adherent THP-1 cells. Bar¼50mm.
(d) Quantification of adherent THP-1 cells. n¼3. Values are means±SEM. *Po0.05. (e) Total protein level of HDFs after treating with 0, 5, 10, and
30mg ml1 xiamenmycin for 3 days. n¼ 3. Values are means±SEM.
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fibroblasts, we immunostained cells for the presence of
proliferating cell nuclear antigen. The ratio of proliferating
cell nuclear antigen positive cells was significantly lower in
xiamenmycin-treated mouse scar sections than that in DMSO-
treated sections at post-incision day 14 (0.207±0.061 vs
0.385±0.116, Po0.05) and day 28 (0.077±0.022 vs
0.191±0.035, Po0.01) (Figure 3a and b), indicating that
the proliferation of stromal cells in fibrotic foci was suppressed
by xiamenmycin. In vitro CCK-8 assays showed that the
proliferation of HDFs was suppressed through incubation with
xiamenmycin at 30mg ml1 for 4 days and 6 days, compared
with those incubated with DMSO, respectively (Figure 3c).
These results suggest that xiamenmycin can reduce excessive
scarring by directly suppressing fibroblast proliferation, in
addition to blocking the retention of inflammatory cells in a
fibrotic microenvironment.
Xiamenmycin attenuates fibroblast activation
Fibroblast activation is a key process in HPS formation.
Myofibroblasts are activated fibroblasts, marked by alpha
smooth muscle actin (a-SMA) expression and stress fiber
formation. Their recruitment and differentiation are usually
triggered by local stimulus of the microenvironment, such as
by transforming growth factor-b1 (TGF-b1), mechanical stress,
or matrix stiffness (Sarrazy et al., 2011). Fibroblast activation
also has important roles in inflammation and mechanical
signal transduction (Vedrenne et al., 2012).
To investigate the effects of xiamenmycin on fibroblast
activation in vivo and in vitro, we evaluated the levels of a-
SMA expression in the scar sections of a mechanical stretch-
induced mouse model and cultured HDFs treated with TGF-
b1. We found that a-SMA expression was noticeably reduced
in xiamenmycin-treated mouse fibrotic tissues compared with
DMSO-treated tissues obtained at post-incision days 14 and
28 (the ratio of a-SMAþ stromal cells is 0.218±0.095 and
0.09±0.022 in xiamenmycin-treated mice vs 0.466±0.092
and 0.222±0.059 in DMSO-treated mice, Po0.01 and
Po0.05, respectively) (Figure 4a and b). We also showed by
immunostaining and western blotting analyses that xiamen-
mycin suppresses TGF-b1-induced a-SMA expression in a
time- and dose-dependent manner in cultured HDFs, respec-
tively (Figure 4c–e). These findings suggest that xiamenmycin
can attenuate the activation of fibroblasts induced by injury
and mechanical stretch in vivo, and by the inflammatory
factor TGF-b1 in vitro.
Xiamenmycin reduces the contractile ability of HDFs in three-
dimensional (3D) collagen gels
Fibroblasts in mechanically stretched microenvironments have
their cytoskeletons remodeled and exhibit a contractive
phenotype (Hinz et al., 2001b; Discher et al., 2005). To
investigate the effects of xiamenmycin on the contractile
ability of HDFs, we performed a 3D-collagen gel fibroblast
contraction assay. After the administration of xiamenmycin,
ranging from 0, 5, 10, to 30mg ml1 for 2, 3, 4, 5, and 6 hours,
the contraction of the collagen gels was monitored by
measuring the gel area. Significant time- and dose-
dependent inhibitory effects of xiamenmycin on the
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Figure 3. Xiamenmycin inhibits human dermal fibroblast (HDF) proliferation.
(a, b) Immunohistochemical staining and quantification of proliferating cell
nuclear antigen (PCNA)-positive cells in scar tissue of post-incision days 14
and 28. Bar¼ 25mm. n¼5. Values are denoted as means±SD. *Po0.05,
**Po0.01. (c) HDF proliferation was assessed by the CCK-8 method. Optical
density (OD) values were measured after treating with xiamenmycin
(30mg ml1) or DMSO (0.01%) for 0, 2, 4, or 6 days. n¼ 3. Values are denoted
as means±SEM. **Po0.01.
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contractile ability of HDFs were observed (Figure 5a and b).
The results indicate that xiamenmycin can efficiently inhibit
the contractile ability of HDFs in 3D collagen gels. This
observation further supports our theory that xiamenmycin can
suppress the effects of mechanical stress on fibroblast
activation.
Xiamenmycin downregulates the phosphorylation of FAK and
p38, and the activation of the small guanosine triphosphatase
(GTPase) RhoA and Cdc42 in HDFs
To further explore the underlying mechanotransduction
mechanisms, the signaling pathways were analyzed. As shown
in Figure 6a and b, the phosphorylation of FAK and p38 was
attenuated by xiamenmycin in both time- and dose-dependent
manners, whereas the phosphorylation of Akt, Erk1/2, and JNK
was not obviously affected. Instead, the small GTPase RhoA
and Cdc42 activation were significantly inhibited when the
HDF cells were treated by 30mg ml1 xiamenmycin for
2 hours compared with those treated with DMSO. However,
no detectable change of Rac1 activation was observed
(Figure 6c).
DISCUSSION
HPS is a complex fibroproliferative disorder and still poorly
understood. However, the roles of inflammation and mechan-
ical stress have been validated in its initiation, maintenance,
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Figure 4. Xiamenmycin inhibits fibroblast activation. (a, b) Immunohistochemistry staining and quantification of alpha smooth muscle actin (a-SMA)-positive
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(c) Immunofluorescence cell staining for a-SMA and F-actin in cultured human dermal fibroblasts (HDFs) after incubation with xiamenmycin (30mg ml1) or
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and progress (Eming et al., 2007; Du et al., 2009; Eckes et al.,
2010; Wynn and Barron, 2010; Ogawa et al., 2012).
Histological investigations have demonstrated that, during
the proliferation stage, HPS displays an exaggerated and
prolonged inflammation characterized by a larger amount of
inflammatory cell infiltration, retention, and activation com-
pared with normal scarring (Eming et al., 2007; Stramer et al.,
2007; Wong et al., 2011). The predominant inflammatory
cells during the proliferation stage are macrophages (Wynn
and Barron, 2010) and lymphocytes, especially CD4þ T
lymphocytes (Wynn, 2004; Wang et al., 2007; Wong et al.,
2011). These inflammatory cells contribute to excessive scar
formation by secreting inflammatory cytokines and
modulating the fibroblast phenotype. The results of our
research indicate that xiamenmycin can reduce CD4þ
lymphocyte and monocyte/macrophage retention in the
murine skin fibrotic foci in vivo, and block adhesion
between monocytes and fibroblasts in vitro. This is
consistent with previous reports that xiamenmycin
was identified as an antagonist for ICAM-1/LFA-1
(Kawamura et al., 2000), and ICAM-1/LFA-1 is crucial in
mediating the recruitment of monocytes/macrophages to
fibrosis lesions and their contacts with fibroblasts and ECM
(Steinhauser et al., 1998; Hubbard and Rothlein, 2000). It has
been demonstrated that, in addition to secreting paracrine
inflammatory factors such as TGF-b1 and modulating
functions of other inflammatory cells, mononuclear cells
such as macrophages can activate fibroblasts by direct
contact (Clayton et al., 1998). Therefore, the inhibition of
fibroblast activation by xiamenmycin may be partially
ascribed to its effects of reducing adhesion between
macrophages and fibroblasts.
The role of mechanical stress in the initiation and progress
of excessive fibrotic diseases has been widely accepted
(Aarabi et al., 2007b; Hinz, 2009; Gurtner et al., 2011;
Ogawa et al., 2012; Wynn and Ramalingam, 2012). Many
studies have found that mechanical stress can modulate the
phenotype of fibroblasts (Kessler et al., 2001; Li et al., 2007),
which can sense elevated mechanical stress, recruit a-SMA to
gain a more contractive phenotype, and facilitate
mechanotransduction (Hinz et al., 2001a; Follonier et al.,
2008). In this study, xiamenmycin reduced the expression of
a-SMA and induced the anti-contractile ability of HDFs in 3D
collagen gels. Further signaling pathway analyses showed that
xiamenmycin can inhibit the phosphorylation of FAK and p38,
as well as the activation of small GTPase RhoA and Cdc42,
which are involved in mechanotransduction. Therefore,
our results suggest that xiamenmycin can attenuate the
effects of mechanical stress on fibroblasts and interrupt
mechanotransduction processes through the multiple
signaling pathways.
A prolonged proliferation stage is another feature of HPS
(Gauglitz et al., 2011). Myofibroblast transformation
and macrophage/lymphocyte retention are pathological
characteristics of the proliferation stage. Our results showed
that xiamenmycin can inhibit myofibroblast trans-
differentiation and reduce retention of monocytes/
macrophages and CD4þ lymphocytes. This observation
suggests that xiamenmycin may suppress HPS by shortening
the prolonged proliferation stage and by attenuating scar
formation.
Compounds targeting either inflammation or mechanical
stress may serve as effective antifibrotic agents. However, anti-
inflammatory compounds such as corticosteroids are limited
in their uses as antifibrotic drugs because of their severe side
effects, and there are still no targets for screening compounds
aimed at mechanotransduction pathways specifically involved
in pathological fibrotic diseases. It has been found that the
FAK, PI3K/AKT, MAPK (JNK, Erk, p38) pathways, and small
GTPases such as RhoA, Cdc42, and Rac1 are involved in
mechanotransduction. Some inhibitors of such kinases or
pathways have resulted in success to some extent (Nagatoya
et al., 2002; Gojo et al., 2007; Ruperez et al., 2007; Hemnes
et al., 2008), but none of them are clinically convenient. Thus,
compounds with inhibitory effects on both inflammation and
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mechanotransduction may be potential candidates for the
development of new antifibrotic drugs, as they may have
stronger antifibrotic efficacy than those solely targeting either
inflammation or mechanotransduction.
In summary, our results show that xiamenmycin
can attenuate HPS formation in a mechanical stretch-
induced mouse model, and further analyses indicate that
xiamenmycin has an anti-HPS effect by targeting two vital
pathogenic origins of HPS, that is, exaggerated inflammation
and mechanical stress, which are also the main pathogenic
routes of other excessive fibrotic diseases, such as cardiac
fibrosis (Diez, 2007), liver cirrhosis (Wells, 2005; Georges
et al., 2007), renal fibrosis (Rohatgi and Flores, 2010;
Sonomura et al., 2012), and lung fibrosis (Cabrera-Benitez
et al., 2012). Therefore, xiamenmycin, with its inhibitory
effects on both the aspects of inflammation and
mechanotransduction, is a promising candidate for treating
excessive fibrotic diseases.
MATERIALS AND METHODS
Sample preparation
Xiamenmycin was isolated from mangrove-derived S. xiamenensis,
using the method described previously (Xu et al., 2012). The
compound was dissolved in DMSO (AppliChem, Darmstadt,
Germany) and further diluted in phosphate-buffered saline before
use. The final concentration of DMSO in the solution was 0.01%.
Animals and hypertrophic scar model
Eight-week-old female C57BL/6 mice were purchased from the
Shanghai Slac Laboratory Animal (Slac, Shanghai, China). All proce-
dures were approved by the Shanghai Jiao Tong University Animal
Care and Use Committee, and all animals were housed under
standard conditions under institution-approved guidelines.
The hypertrophic scar model was established according to a
published method (Aarabi et al., 2007a). In brief, a 2-cm full-
thickness incision was created and sutured at the dorsal midline of
each mouse. Four days post incision, the sutures were removed,
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(HDFs). (b) Levels of phosphorylated FAK, Akt, p38, JNK, and Erk1/2 after treatment with xiamenmycin (0, 5, 10, or 30mg ml1) for 12 hours were detected in
in vitro cultured HDFs. (c) Levels of active and total RhoA, Cdc42, and Rac1 were detected by pull down assays after incubation with xiamenmycin (30mg ml 1)
for 2 hours. n¼ 3. Values are denoted as means±SEM. *Po0.05, **Po0.01.
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mechanical stretch devices were sutured overlying the incisions, and
stretching was carried out from day 4 to day 14 post incision. Twenty
mice were divided into two groups, with one group of mice
intraperitoneally injected with xiamenmycin (10 mg kg 1 dissolved
in 1% DMSO) and another group with DMSO (1%, 5 ml kg 1), once
every day from day 4 to day 14 post incision. The total scar areas
were measured at post-incision days 14, 21, and 28. Half mice of
both groups were killed at day 14 and half at day 28 post incision.
Scar specimens were harvested for further analyses.
Cell culture
Primary HDFs were obtained from adolescent foreskin tissue with
written informed consent according to Declaration of Helsinki
Principles and maintained in DMEM (11,965, Gibco, Grand Island,
NY) supplemented with 10% fetal bovine serum (Gibco-BRL,
Gaithersburg, MD), 100 U ml 1 penicillin, and 100mg ml 1 strepto-
mycin (Solarbio, Beijing, China). THP-1 cells were maintained in
RPMI 1640 medium (Gibco), supplemented with 10% fetal bovine
serum, 100 U ml 1 penicillin, 100mg ml 1 streptomycin, and
0.5 mM/l b-mercaptoethanol (Gibco). Both cell lines were incubated
at 37 1C in a humidified atmosphere with 5% CO2. Primary fibroblasts
of passages 6–8 were used.
Histology and immunohistochemistry
Paraformaldehyde-fixed paraffin-embedded tissue sections (5mm)
were stained with Picrosirius red (Fluka, Buchs, Switzerland). The
scar elevation index was measured as described in previous publica-
tions (Wu et al., 2011). For immunohistochemical staining, the
sections were detected with primary antibodies against a-SMA
(Sigma-Aldrich, St Louis, MO), proliferating cell nuclear antigen
(Epitomics, Burlingame, CA), CD4, and MOMA2 (monocytes/
macrophages marker) (Abcam, Cambridge, MA) overnight at 4 1C.
After incubation with the appropriate secondary antibodies, the
sections were developed with diaminobenzidine and counterstained
with hematoxylin. Images were processed for publication using
Adobe Photoshop CS4.
Total protein synthesis assay
After treating with 0, 5, 10, and 30mg ml 1 xiamenmycin for 3 days,
identical number of HDFs (4 105 cells) were harvested. The total
protein was determined by microplate BCA method using a BCA
protein assay kit (Pierce, Rockford, IL) according to the manufacturer’s
instructions.
Adhesion assay
Adhesion assays were carried out according to previous publications
(Hundhausen et al., 2003; Pfaff et al., 2008). HDFs were seeded in
24-well plates and allowed to grow to confluence. THP-1 cells were
fluorescently labeled using 2.5mM calcein AM (Dojindo, Kumamoto,
Japan). Next, 500ml THP-1 cell suspension at a density of 1 105
cells per ml in 0, 5, 10, or 30mg ml 1 xiamenmycin was added into
each well. The plates were centrifuged at 1,000 r.p.m. for 3 minutes,
and then incubated at 37 1C for 60 minutes. The medium and the
nonadherent THP-1 cells were removed, and each well was washed
with phosphate-buffered saline three times. Adherent THP-1 cells
were microscopically quantified at 100-fold magnification in four
random visual fields of each well and photographed with an Axiovert
200 inverted fluorescence microscope (Zeiss, Jena, Germany).
Fibroblast proliferation assay
Proliferation was determined using a standard CCK-8 (Dojindo) assay
according to the manufacturer’s instructions. HDFs were seeded in
96-well plates (100ml per well) at an initial density of 2.5 104 cells
per ml. The medium was replaced after 24 hours, and 30mg ml 1
xiamenmycin was added. The medium was changed once every 2
days, and optical density values were measured at 0, 2, 3, 4, and 6
days.
Immunofluorescence cell staining
HDFs at a density of 2 103 cells per well were seeded on cover
slides in 24-well plates and incubated overnight. Either 30mg ml 1
xiamenmycin or 0.01% DMSO was added after the cells were serum-
starved for 24 hours. For F-actin staining, cells were incubated with
phalloidin-FITC (Sigma-Aldrich) for 75 minutes at room temperature.
For a-SMA staining, cells were incubated with primary antibodies
against a-SMA (Sigma-Aldrich) for 75 minutes at room temperature,
followed by an Alexa Fluor 594-conjugated secondary antibody.
Immunofluorescence signals were captured using confocal micro-
scopy (LSM 510, METALaser Scanning Microscope, Zeiss).
Collagen gel contraction assay
HDFs at a density of 6 104 cells per ml were seeded onto 32 mm
bacteriological plates (2 ml per dish) in DMEM supplemented with
10% fetal bovine serum, antibiotics, sodium ascorbate (50mg ml 1),
and 0.3 mg ml 1 of acid-extracted collagen I from newborn calf skin
(IBFB, Leipzig, Germany) as previously described (Zhang et al.,
2006a), with 0, 5, 10, or 30mg ml 1 xiamenmycin in different
plates. The cells were cultured at 37 1C for 60 minutes to allow
collagen polymerization. The gels were released from plates by tilting
plates slightly. Gradual gel contraction was monitored by measuring
the gel area at successive time points up to 6 hours. The data show the
means±SEM of three independent experiments, each conducted in
triplicate.
Western blotting
Cells were lysed with radio-immunoprecipitation assay lysis buffer
(Beyotime, Jiangsu, China) supplemented with 1 mM phenylmethyl-
sulfonyl fluoride (Adamas beta, Shanghai, China). The primary
antibodies used included the following: a-SMA (Abcam, 1:500),
FAK (BD Biosciences, San Diego, CA, 1:500), p-FAK Tyr397 (Milli-
pore, Billerica, MA, 1:1,000), Akt, p-Akt Ser473, JNK, p-JNK Thr183/
Tyr185, Erk1/2, p-Erk1/2 Thr202/Tyr204, p38, and p-p38 Thr180/
Tyr182 (Cell Signaling Technology, Beverly, MA, 1:1,000). Signals on
the membranes were detected by an Odyssey infrared imaging system
(LI-COR, Lincoln, NE) after incubating with the IRDye 680 anti-
mouse (LI-COR, 1:20,000) and IRDye 800 anti-rabbit (LI-COR,
1:10,000) secondary antibodies for 1 hour at room temperature.
Pull down assay
Pull down assays were performed as reported (Zhang et al., 2006b).
Confluent HDFs in 100 mm dishes were serum-starved for 24 hours
and treated with xiamenmycin (30mg ml 1) or DMSO (0.01%) for
2 hours. The primary antibodies used included the following:
mouse primary antibody against Rac1 (Millipore, 1:1,000) and
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rabbit primary antibody against RhoA, Cdc42 (Cell Signaling
Technology, 1:1,000).
Statistical analysis
Statistical differences were calculated using the two-tailed Student’s
t-test. Po0.05 was considered statistically significant.
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